PITTSBURGH & LONDON--(BUSINESS WIRE)--Helomics, a privately-held, comprehensive personalised healthcare company (headquartered in Pittsburgh, Pennsylvania) that develops innovative next-generation diagnostics for the oncology field, announced today that it is delighted to be supporting the UK’s Personalised Healthcare Alliance. As a founding contributor to the Alliance, Helomics joins the likes of AstraZeneca, Biogen Idec, Cancer Research UK, Epistem, Horizon Discovery, Myeloma UK and MRC Technology in aiding the development of this important initiative. The priorities of the Alliance are to promote the UK's many strengths in the personalised healthcare sector, to bring a growing community of “challenge agents” together for the widespread dialogue that will be fundamental to UK leadership in this space, to serve as an independent presence that reflects the breadth and value of the UK’s contribution, and to help forge better health for UK citizens and UK plc.
Neil Campbell, President and CEO of Helomics, said, “Helomics believes that the UK has the potential to lead innovation in the global personalised healthcare space. Realising the promise of precision medicine will require global collaboration. We are therefore very pleased to support the Personalised Healthcare Alliance and its important work.”
Nigel Gaymond, the Executive Chairman of the Personalised Healthcare Alliance, said, “We are delighted that Helomics joins Biogen Idec as an overseas supporter, along with prominent UK organisations, in recognising the value of supporting an independent presence in this emerging sector. It will take a village of global partners to accelerate the development and adoption of personalised healthcare innovations, and the Alliance is grateful to Helomics for its support in this endeavour."
About Helomics™ Corporation
Helomics is a comprehensive personalised healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by utilising a proprietary set of laboratory platforms and our product science as a service commercialisation model to allow physicians to characterise malignant tumours. Helomics' novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual's cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.
About the Personalised Healthcare Alliance
The Personalised Healthcare Alliance is articulating a vision for personalised healthcare in the UK while working to improve the health and life science environment and to mobilise the UK to excel in this emerging sector. The Alliance unites a group of strategic stakeholders with a remit to actively break down barriers and showcase UK capabilities.